Intraarterially administered abciximab as an adjuvant thrombolytic therapy: Report of three cases

American Journal of Neuroradiology

Volumn 23, Issue 3, 2002, Pages 447-451

  Kwon, O Ki ^a   Lee, Ki Jae ^a   Han, Moon Hee ^a   Oh, Chang Wan ^a   Han, Dae Hee ^a   Koh, Young Cho ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; UROKINASE;

ADJUVANT THERAPY; ADULT; ARTICLE; BLOOD CLOT LYSIS; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; RECANALIZATION; THROMBOSIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CEREBRAL ANGIOGRAPHY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; INTRACRANIAL THROMBOSIS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036128776     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Rescue treatment of acute parent vessel thrombosis with glycoprotein IIb/IIIa inhibitor during coil embolization
3. Abciximab in acute ischemic stroke: A randomized, double-blind, placebo-controlled, dose-escalation study
4. Basilar artery rethrombosis: Successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor
5. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction
6. GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab
7. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis"
8. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets
9. Factor V activity of platelets: Evidence for an activated factor V molecule and for a platelet activator
10. The modulation of thrombin activation of factor VIII by calcium ions, phospholipids and platelets
11. Platelet-coagulant protein interactions
12. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin
13. Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
14. Effect of heparin and heparin fractions on platelet aggregation
15. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
16. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial
17. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
18. Local intraarterial fibrinolysis in the carotid territory